Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications.

Biljana Tubic,Vanda Marković-Peković,Saša Jungić,Eleonora Allocati,Brian Godman

Medicine access @ point of care（2021）

引用 10|浏览0

暂无评分

摘要

The limited use of mAbs including biosimilars needs to be addressed in B&H to improve the future care of patients within finite resources. We will monitor these developments.

查看译文

关键词

Bosnia and Herzegovina,Monoclonal antibodies,biosimilars,demand-side measures,insulin glargine,regulatory approach

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要